Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Capital Expenditures (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed Capital Expenditures for 5 consecutive years, with $8000.0 as the latest value for Q1 2025.

  • Quarterly Capital Expenditures changed N/A to $8000.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $8000.0 through Dec 2025, down 72.41% year-over-year, with the annual reading at $8000.0 for FY2025, 72.41% down from the prior year.
  • Capital Expenditures hit $8000.0 in Q1 2025 for Kezar Life Sciences, down from $11000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $1.2 million in Q1 2023 to a low of -$551000.0 in Q3 2022.
  • Historically, Capital Expenditures has averaged $179692.3 across 5 years, with a median of $24000.0 in 2021.
  • Biggest YoY gain for Capital Expenditures was 2533.33% in 2022; the steepest drop was 2219.23% in 2022.
  • Year by year, Capital Expenditures stood at $392000.0 in 2021, then crashed by 108.67% to -$34000.0 in 2022, then skyrocketed by 102.94% to $1000.0 in 2023, then skyrocketed by 1000.0% to $11000.0 in 2024, then decreased by 27.27% to $8000.0 in 2025.
  • Business Quant data shows Capital Expenditures for KZR at $8000.0 in Q1 2025, $11000.0 in Q4 2024, and $18000.0 in Q3 2024.